// App-Quantinova.ai

GS2-07 : Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)

Researchers

Presenter

  • Miguel Martn

Principal Investigators

  • Manuel Ruz-Borrego

  • Eva Carrasco

  • Eva Ciruelos

  • Montserrat Muoz

  • Begoa Bermejo

  • Mireia Margeli

  • Nicholas Turner

  • Maribel Casas

  • Antonio Antn

  • Tibor Csszi

  • Massimo Corsaro

  • Laura Murillo

  • Serafn Morales

  • Emilio Alba

  • Cynthia H Bartlett

  • Maria Koehler

  • Angel Guerrero

  • Zsuzsanna Kahan

  • Miguel Gil-Gil

Medical Centers

  • Instituto de Investigación Sanitaria Gregorio Marañón. CIBERONC-ISCIII. GEICAM Spanish Breast Cancer Group, Madrid, Spain

  • Vienna Cancer Center, Medical University Vienna and Vienna Hospital Association. Central European Cooperative Oncology Group (CECOG), Viena, Austria

  • Hospital Universitario Virgen Macarena, GEICAM Spanish Breast Cancer Group, Seville, Spain

  • GEICAM Spanish Breast Cancer Group, Madrid, Spain

  • Hospital Universitario 12 de Octubre. GEICAM Spanish Breast Cancer Group, Madrid, Spain

  • Hospital Universitari Clinic de Barcelona. Spanish Breast Cancer Group, Barcelona, Spain

  • Clínico Universitario de Valencia, INCLIVA Valencia. CIBERONC-ISCIII. GEICAM Spanish Breast Cancer Group, Valencia, Spain

  • ARGO Group, Catalan Institut of Oncology, Hospital Universitari Germans Trias i Pujol, Badalona. GEICAM Spanish Breast Cancer Group, Barcelona, Spain

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • Hospital Universitario Miguel Servet, Geicam Spanish Breast Cancer Group, Zaragoza, Spain

  • Jasz-Nagykun Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary

  • Pfizer Inc, Milan, Italy

  • Hospital Clínico de Zaragoza Lozano Blesa. GEICAM Spanish Breast Cancer Group, Zaragoza, Spain

  • Hospital Universitario Arnau de Vilanova. GEICAM Spanish Breast Cancer Group, Lleida, Spain

  • Hospital Clínico Universitario Virgen de la Victoria, Málaga, ES; 18Instituto de Investigación Biomédica de Málaga, IBIMA. CIBERONC-ISCIII. GEICAM Spanish Breast Cancer Group, Málaga, Spain

  • Pfizer Inc (during study conduct), New York, NY

  • Jounce Therapeutics, Cambridge, MA

  • Instituto Valenciano de Oncologia, GEICAM Spanish Breast Cancer Group, Valencia, Spain

  • Department of Ophthalmology, University of Szeged, Szeged, Hungary

  • Institut Catalá d’Oncologia (ICO), L’Hospitalet de Llobregat. GEICAM Spanish Breast Cancer Group, Barcelona, Spain

Locations

  • Spain

  • Austria

  • United Kingdom

  • Hungary

  • Italy

  • United States

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Estrogen Receptor 1

  • Circulating DNA

Drug/Treatment

  • Capecitabine

  • Palbociclib

Outcome

  • N/A

Study Design

  • Randomized

  • Superiority

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved